ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print
Health Technology

AnGes, Inc.

Business Summary

AnGes, Inc. engages in the research and development of gene-based medical products. It offers genetic medicines such as hepatocyte growth factor (HGF) genetic medicines, NF-KB decoy oligo and hemagglutinating virus of Japan envelope (HVJ-E) non-viral vector, and others. It is also involved in the research and development of medical equipment, which improves blood circulation by regenerating blood vessels and NfkB which controls various inflammations. The company was founded on December 17, 1999 and is headquartered in Ibaraki, Japan.

Financial Highlights

Dec 2022 JPYUSD
Gross Profit-2,920.27M-22.20M
Operating income-16,316.80M-124.05M
Income before tax-14,716.99M-111.89M
Net income-14,714.77M-111.87M
Diluted EPS-94.29-0.71
Dividends Per Share00
Total Assets38,820.71M294.21M
Total liabilities8,395.30M63.62M
Total equity30,425.40M230.59M
Operating cash flow-11,214.24M-85.26M
Currency in JPYCurrency in USD

Historical Data

 Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022
Revenue 610.05M 326.75M 39.99M 64.14M 67.06M
Gross Profit 418.87M 235.16M 12.06M -2,410.09M -2,920.27M
Operating income -3,065.25M -3,270.00M -5,599.39M -15,632.08M -16,316.80M
Income before tax -3,003.00M -3,751.60M -4,204.95M -13,735.29M -14,716.99M
Net income -2,996.62M -3,750.82M -4,209.51M -13,675.58M -14,714.77M
EBITDA -3,057.39M -3,262.68M -5,591.80M -13,206.00M -13,414.97M
Diluted EPS -34.46 -35.81 -35.32 -92.85 -94.29
Dividends Per Share 0 0 0 0 0
Total Assets 8,050.67M 12,524.60M 38,354.61M 45,455.74M 38,820.71M
Total liabilities 316.21M 469.24M 5,674.93M 6,821.00M 8,395.30M
Total equity 7,734.45M 12,055.35M 32,679.67M 38,634.74M 30,425.40M
Operating cash flow -2,522.50M -2,179.91M -2,961.32M -11,380.54M -11,214.24M
 Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022
Revenue 5.52M 2.99M 0.37M 0.58M 0.50M
Gross Profit 3.79M 2.15M 0.11M -21.93M -22.20M
Operating income -27.75M -29.99M -52.44M -142.27M -124.05M
Income before tax -27.19M -34.41M -39.38M -125.01M -111.89M
Net income -27.13M -34.40M -39.42M -124.46M -111.87M
EBITDA -27.68M -29.92M -52.37M -120.19M -101.99M
Diluted EPS -0.31 -0.32 -0.33 -0.84 -0.71
Dividends Per Share 0 0 0 0 0
Total Assets 73.37M 115.24M 371.49M 394.73M 294.21M
Total liabilities 2.88M 4.31M 54.96M 59.23M 63.62M
Total equity 70.49M 110.93M 316.52M 335.50M 230.59M
Operating cash flow -22.83M -19.99M -27.73M -103.57M -85.26M

Valuation Measures

Dec 2022
Operating margin-24,331.28%
Profit margin-21,942.36%


  • President & Representative Director: Ei Yamada
  • Director, Executive Officer & Manager-Finance: Tetsuji Yoneo
  • Director & Manager-Drug Discovery Research: Kazuo Suzuki
  • Executive Officer, Manager-R&D Promotion: Hajime Watanabe
  • Manager-Accounting: Jun Sakurai


  • Shionogi & Co., Ltd. (0.6%)
  • Dimensional Fund Advisors LP (0.1%)
  • Siemens Fonds Invest GmbH (0.0%)
  • SSgA Funds Management, Inc. (0.0%)
  • SPARX Asset Management Co., Ltd. (0.0%)
  • Dimensional Fund Advisors Ltd. (0.0%)

Contact Details

  • Website:
  • Address: Saito Bio-Incubator, 1/F, 7-7-15 Saito-Asagi, Osaka, 567-0085, Japan
  • Phone: +81.72.643.3590

Related Companies

  • Emendo Biotherapeutics, Inc.
  • AnGes USA, Inc.
  • AnGes Euro Ltd.


  • Athira Pharma, Inc.
  • Editas Medicine, Inc.
  • Sienna Biopharmaceuticals, Inc.
Last Updated on 22 Sep, 2023

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more